Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C12H17N3O |
| Molecular Weight | 219.2829 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)C1=CC(C#N)=C(N)C=C1
InChI
InChIKey=BUXRLJCGHZZYNE-UHFFFAOYSA-N
InChI=1S/C12H17N3O/c1-8(2)15-7-12(16)9-3-4-11(14)10(5-9)6-13/h3-5,8,12,15-16H,7,14H2,1-2H3
Cimaterol is a chemically stable nonselective agonist β1-, β2-, and β3-adrenoceptors. Cimaterol is used in sport as a stimulant and a fat burner that assists bodybuilders and strength athletes to get rid of body fats. Aside from shedding off fats, another benefit for using cimaterol for athletes is a boost in strength as well as an increase in muscle size or lean body mass. The increase in muscle size has been seen in previous animal studies when cimaterol is used. However, the reason behind the muscle gain is not identified yet, but the body has a very different response compared from taking in anabolic steroids. Experts in the field are saying that the increased nitrogen retention, that is known to cause by cimaterol, maybe the reason behind the muscle gain. Another great thing about Cimaterol is that, it can improve blood flow.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P13945 Gene ID: 155.0 Gene Symbol: ADRB3 Target Organism: Homo sapiens (Human) |
6.62 null [pEC50] | ||
Target ID: P08588 Gene ID: 153.0 Gene Symbol: ADRB1 Target Organism: Homo sapiens (Human) |
8.13 null [pEC50] | ||
Target ID: P07550|||Q53GA6|||Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) |
8.78 null [pEC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
PubMed
| Title | Date | PubMed |
|---|---|---|
| Integrated acquisition of analytical and biopharmaceutical screening data for beta-adrenergic-drugs employing diversified macrocycle supported potentiometric detection in HPLC systems. | 2002 Aug |
|
| Effect of dietary clenbuterol and cimaterol on muscle composition, beta-adrenergic and androgen receptor concentrations in broiler chickens. | 2004 Apr |
|
| Determination of clenbuterol, salbutamol, and cimaterol in bovine retina by electrospray ionization-liquid chromatography-tandem mass spectrometry. | 2004 Jan-Feb |
|
| Evidence for a secondary state of the human beta3-adrenoceptor. | 2005 Dec |
|
| Determination of beta-agonists in liver and retina by liquid chromatography-tandem mass spectrometry. | 2005 Jan-Feb |
|
| Determination of beta-agonist residues in bovine urine using liquid chromatography-tandem mass spectrometry. | 2005 Jan-Feb |
|
| Site of action of beta-ligands at the human beta1-adrenoceptor. | 2005 Jun |
|
| [Simultaneous determination of cimaterol, clenbuterol and salbutamol in feeds by capillary zone electrophoresis]. | 2005 May |
|
| Field-amplified on-line sample stacking for separation and determination of cimaterol, clenbuterol and salbutamol using capillary electrophoresis. | 2006 Aug 25 |
|
| Multiple GPCR conformations and signalling pathways: implications for antagonist affinity estimates. | 2007 Aug |
|
| Validation of radioimmunoassay screening methods for beta-agonists in bovine liver according to Commission Decision 2002/657/EC. | 2008 Dec |
|
| [Multi-residue analysis of 10 beta2-agonists in animal tissues using gas chromatography-mass spectrometry]. | 2008 Jan |
|
| Steroid and beta-adrenergic receptor modifications in target organs of broiler chickens fed with a diet containing beta2-adrenergic agents. | 2008 Jun |
|
| [Simultaneous determination of nine beta-agonist residues in animal derived foods by ultra performance liquid chromatography-tandem mass spectrometry]. | 2008 Nov |
|
| Evaluation of the illegal use of clenbuterol in Portuguese cattle farms from drinking water, urine, hair and feed samples. | 2009 Jun |
|
| Regression-based approach for testing the association between multi-region haplotype configuration and complex trait. | 2009 Sep 17 |
|
| Generic sample preparation combined with high-resolution liquid chromatography-time-of-flight mass spectrometry for unification of urine screening in doping-control laboratories. | 2010 Apr |
|
| [Determination of fifteen beta-agonists in animal urine by high performance liquid chromatography-tandem mass spectrometry]. | 2010 Aug |
|
| Protein microarray: sensitive and effective immunodetection for drug residues. | 2010 Feb 16 |
|
| A full pharmacological analysis of the three turkey β-adrenoceptors and comparison with the human β-adrenoceptors. | 2010 Nov 30 |
Patents
Sample Use Guides
bodybuilders and strength athletes: Both oral and injectable variants are available for cimaterol. The injectable is subcutaneously administered. Effective dosage, based on research and study, is approximately 0.15 milligram per kilogram, for both male and female. With this dosage, users can have beneficial gains from the drug for subcutaneously administered. New users of this drug are advised to start at the low-end of the spectrum to minimize the unbearable or dangerous side effects.
Route of Administration:
Other
H-cAMP accumulation in response to cimaterol in CHO β1 cells, CHO β2 cells, and CHO β3 cells were meacured. Cimaterol stimulated responses were 96.9 ± 1.1% (log EC50 = −8.13 ± 0.03, n = 9), 98.9 ± 1.7% (log EC50 = −8.78 ± 0.06, n = 9), and 89.6 ± 1.9% (log EC50 = −6.62 ± 0.06, n = 9) of the isoprenaline maximum response at the human β1-, β2-, and β3-adrenoceptors, respectively
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
CIMATEROL
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY | |||
|
SUB06276MIG
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY | |||
|
5773
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY | |||
|
C76017
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY | |||
|
2755
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY | |||
|
100000081036
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY | |||
|
m3551
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
DTXSID2045652
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY | |||
|
54239-37-1
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY | |||
|
C047411
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL1374751
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY | |||
|
ZPY8VRF0GB
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY | |||
|
W-89
Created by
admin on Fri Dec 15 16:31:17 GMT 2023 , Edited by admin on Fri Dec 15 16:31:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
